Search Medical Condition
Please enter condition
Please choose location
 

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (3201) clinical trials

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD. ClinicalTrials.gov identifier: NCT02465567 https://www.pearltherapeutics.com/pipeline-overview

Phase N/A

This is a randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of BGF MDI 320/14.4/9.6 μg and BGF MDI 160/14.4/9.6 μg relative to GFF MDI 14.4/9.6 μg and BFF MDI 320/9.6 μg over a 52-week treatment period in 8,000 subjects with moderate to very severe COPD ...

Phase

The study will determine how well the treatment with the study drug called nintedanib can demonstrate a slowing in the rate of lung scarring (or fibrosis) and how well the study treatment has an effect on the skin thickening.

Phase

This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure patients with 30%=left ventricular ejection fraction (LVEF)=35%%, and in particular, ...

Phase

The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) = 35% despite being treated ...

Phase N/A

ILDs, also referred to as diffuse parenchymal lung diseases (DPLD), encompasses a large group of over 200 pulmonary disorders. The clinical assessment of a patient with ILD requires a multidisciplinary approach: medical history including occupational, environmental, medication, smoking and family history, physical examination, laboratory investigation, lung function testing together with ...

Phase

Exact Sciences Corporation, the sponsor of this study, is collecting blood samples to better understand the biomarkers of patients with abnormal CT scans or lung cancer nodules. Biomarkers are biologic features found in the blood and may be related to lung disease risk and detection. The sponsor will also collect ...

Phase N/A

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this ...

Phase

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute ...

Phase N/A

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

Infants will receive a placebo or furosemide for 28 days. Blood samples will be collected for pharmacokinetic analysis.Premature infants will be randomized to receive placebo or furosemide in a dose escalating approach. Follow up information will be collected up to 7 days after the last dose and at 36 weeks ...

Phase